CURRENT PRACTICE INSIGHTS into ONCOLOGY

PHARMO

An experienced sparring partner for all your EU healthcare questions

Patient-centric data derived from real-life healthcare settings is a key element in generating evidence for decision-making by healthcare stakeholders. Our clients use this evidence to demonstrate safety, effectiveness and quality of care. PHARMO is specialised in generating this evidence, by means of observational and real-life research with data from current treatment practice. We provide expert data analysis to support regulatory, market access and treatment decisions throughout a product life-cycle.

PHARMO has delivered its tailor-made services for more than 600 late-phase studies across a wide range of therapeutic areas.

For healthcare research using medical data from cancer patients, PHARMO has access to an excellent observational framework by linking the PHARMO Database Network to 1) the Eindhoven Cancer Registry (ECR) which is maintained by the Netherlands Comprehensive Cancer Organisation (IKNL), and 2) a nationwide network and registry of histo- and cytopathology which is maintained by the PALGA foundation.

PHARMO Database Network
Rapid access to primary and secondary healthcare data



We are continuing to expand our capabilities in Europe by collaborating with European healthcare database partners.

Examples of information available

Cancer Registry

Newly diagnosed cancer patients from 1998 onwards

- *Cancer diagnosis*
- *Tumour staging (UICC TNM Classification)*
- *Site (topography) and morphology (histology) according to ICD-O*
- *Receptor status*

Treatment received

- *Initial treatment (surgery, chemotherapy, radiotherapy)*

Pathology Registry

Abstracts of the pathology reports

- *Histological, cytological and autopsy examinations*
- *Diagnostic terms in line with SNOMED terminology*
- *Immunohistochemistry and molecular pathology (e.g. KRAS/ EGFR/ BRAF/ ALK status)*

Innovation by Observation

What can we do for you?

Observational research

- Drug utilisation
  - *Initial treatment (surgery, chemotherapy, radiotherapy)*
  - *Follow-up treatment via in-patient (hospital) pharmacy: chemotherapy regimens (first-, second-, and third-line)*
- Patient characteristics
  - *Age, gender, SES*
  - *Tumour staging (UICC TNM Classification)*
  - *Receptor / mutational status*
  - *Laboratory values (e.g. prostate specific antigen (PSA) levels)*
- Safety outcomes
  - *Late effects of treatment*
  - *Survival*
  - *Post-Authorisation Safety Study (PASS)*
- Healthcare resource utilisation
  - *Medication use*
  - *Hospitalisations*

Additional patient-centric data collection

- *Patient reported outcomes (PRO)*
- *Physician reported outcomes*
- *Patient monitoring*
- *Disease management support*

Expert consultancy

- *Risk management*
- *Market access*
- *Clinical trial design*

We create tailor-made cohorts and we can collect additional patient-centric data if this suits your needs.

Further information on our various publications and studies in which we are involved can be found on our website: **www.pharmo.com**

Tell us about your healthcare research questions: **pharmo@pharmo.com**

PHARMO

WWW.PHARMO.COM